Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

MLA

Joshua K. Kays, et al. “Three Cachexia Phenotypes and the Impact of Fat‐only Loss on Survival in FOLFIRINOX Therapy for Pancreatic Cancer.” Journal of Cachexia, Sarcopenia and Muscle, vol. 9, no. 4, Aug. 2018, pp. 673–84. EBSCOhost, https://doi.org/10.1002/jcsm.12307.

APA

Joshua K. Kays, Safi Shahda, Melissa Stanley, Teresa M. Bell, Bert H. O’Neill, Marc D. Kohli, Marion E. Couch, Leonidas G. Koniaris, & Teresa A. Zimmers. (2018). Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle, 9(4), 673–684. https://doi.org/10.1002/jcsm.12307

Chicago

Joshua K. Kays, Safi Shahda, Melissa Stanley, Teresa M. Bell, Bert H. O’Neill, Marc D. Kohli, Marion E. Couch, Leonidas G. Koniaris, and Teresa A. Zimmers. 2018. “Three Cachexia Phenotypes and the Impact of Fat‐only Loss on Survival in FOLFIRINOX Therapy for Pancreatic Cancer.” Journal of Cachexia, Sarcopenia and Muscle 9 (4): 673–84. doi:10.1002/jcsm.12307.